指南与共识神经肌肉病

化疗诱导的周围神经病变预防试验设计:ACTTION推荐

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.
指南 / 共识 · Neurology · 2018-07-27

本文由ACTTION-CONCEPPT会议的多学科专家讨论制定,针对化疗诱导的周围神经病变(CIPN)预防性随机对照试验的设计提出推荐,涵盖入组标准选择、结局指标与终点选择(包括化疗剂量调整)、研究治疗对化疗疗效的潜在影响以及样本量估计等方面,旨在提高CIPN预防试验的质量和检测灵敏度,加速有效疗法的识别。

要点

  • CIPN是神经毒性化疗常见且可能限制剂量的副作用,目前无预防疗法。
  • 预防CIPN的随机对照试验设计缺乏共识,阻碍新疗法开发。
  • 推荐关注入组标准、结局指标(含化疗剂量调整)、对化疗疗效影响及样本量估计。

核心结论

  • 关注本文所述设计考虑和推荐有望提高CIPN预防试验的质量和检测灵敏度,从而加速有效疗法的识别。

研究设计与样本

  • ACTTION-CONCEPPT会议汇集神经科医生、肿瘤科医生、药师、临床试验专家、统计学家和监管专家,讨论CIPN预防试验的设计考虑并提供推荐。

主要发现

  • 评估CIPN预防疗法的阳性随机对照试验数量少,难以为未来试验设计提供指导。
  • 该领域主要设计特征缺乏共识,给新疗法开发带来挑战。

关键数值与推荐

  • 试验设计需考虑入组标准选择(如癌症类型、化疗类型、是否纳入已有神经病变)。
  • 试验设计需考虑结局指标和终点的选择,包括纳入化疗剂量调整的指标,因其可能影响CIPN发生率和严重程度。
  • 试验设计需考虑研究疗法对化疗疗效的潜在影响。
  • 试验设计需考虑样本量估计。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side effect of neurotoxic chemotherapies. No therapies are available to prevent CIPN. The small number of positive randomized clinical trials (RCTs) evaluating preventive therapies for CIPN provide little guidance to inform the design of future trials. Moreover, the lack of consensus regarding major design features in this area poses challenges to development of new therapies. An Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION)-Consortium on Clinical Endpoints and Procedures for Peripheral Neuropathy Trials (CONCEPPT) meeting attended by neurologists, oncologists, pharmacists, clinical trialists, statisticians, and regulatory experts was convened to discuss design considerations and provide recommendations for CIPN prevention trials. This article outlines considerations related to design of RCTs that evaluate preventive therapies for CIPN including (1) selection of eligibility criteria (e.g., cancer types, chemotherapy types, inclusion of preexisting neuropathy); (2) selection of outcome measures and endpoints, including those that incorporate alterations in chemotherapy dosing, which may affect the rate of CIPN development and its severity; (3) potential effects of the investigational therapy on the efficacy of chemotherapy; and (4) sample size estimation. Our hope is that attention to the design considerations and recommendations outlined in this article will improve the quality and assay sensitivity of CIPN prevention trials and thereby accelerate the identification of efficacious therapies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Gewandter JS, Brell J, Cavaletti G, et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology. 2018. PMID: 30054438. doi:10.1212/WNL.0000000000006083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。